Healthcare provider profile · identity verified

Adina Valceanu

Internal Medicine · JAMAICA, NY · NPI 1174826929

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	362	117
Amlodipine Besylate	Amlodipine Besylate	245	78
Losartan Potassium	Losartan Potassium	182	69
Famotidine	Famotidine	177	62
Metformin Hcl	Metformin Hcl	149	50
Fluticasone Propionate	Fluticasone Propionate	143	48
Omeprazole	Omeprazole	142	41
Gabapentin	Gabapentin	124	49
Hydrochlorothiazide	Hydrochlorothiazide	122	42
Lisinopril	Lisinopril	116	35
Alendronate Sodium	Alendronate Sodium	106	29
Rosuvastatin Calcium	Rosuvastatin Calcium	103	35
Alcohol Prep Pads	Alcohol Antiseptic Pads	92	33
Levothyroxine Sodium	Levothyroxine Sodium	88	32
Metoprolol Succinate	Metoprolol Succinate	82	27
Diclofenac Sodium	Diclofenac Sodium	76	35
Tamsulosin Hcl	Tamsulosin Hcl	75	25
Albuterol Sulfate Hfa	Albuterol Sulfate	70	21
Metoprolol Tartrate	Metoprolol Tartrate	70	23
Januvia	Sitagliptin Phosphate	67	19
Jardiance	Empagliflozin	63	18
Simvastatin	Simvastatin	60	18
Nifedipine Er	Nifedipine	59	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	19
Eliquis	Apixaban	50	11
Glipizide	Glipizide	50	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	49	12
Pantoprazole Sodium	Pantoprazole Sodium	49	23
Janumet	Sitagliptin Phos/Metformin Hcl	47	16
Single Use Swab	Alcohol Antiseptic Pads	47	25
Ramipril	Ramipril	46	13
Pioglitazone Hcl	Pioglitazone Hcl	45	14
Furosemide	Furosemide	42	17
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	41	15
Finasteride	Finasteride	40	12
Hydralazine Hcl	Hydralazine Hcl	35	14
Hydrocortisone	Hydrocortisone	34	19
Ozempic	Semaglutide	34	15
Carvedilol	Carvedilol	32	suppressed
Donepezil Hcl	Donepezil Hcl	32	suppressed
Montelukast Sodium	Montelukast Sodium	32	12
Pravastatin Sodium	Pravastatin Sodium	32	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	32	16
Ezetimibe	Ezetimibe	31	12
Trulicity	Dulaglutide	29	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	26	14
Labetalol Hcl	Labetalol Hcl	26	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Novolog Flexpen	Insulin Aspart	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Acyclovir	Acyclovir	20	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	15
Prednisone	Prednisone	20	suppressed
Ranolazine Er	Ranolazine	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Nystatin	Nystatin	18	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	17	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	16	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Ammonium Lactate	Ammonium Lactate	13	suppressed
Gavilyte-G	Peg3350/Sod Sulf,bicarb,cl/Kcl	13	13
Latanoprost	Latanoprost	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Atenolol	Atenolol	11	suppressed
Azithromycin	Azithromycin	11	11
Lorazepam	Lorazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error